Literature DB >> 12433774

Sildenafil for "blue babies". Such unlicensed drug use might be justified as last resort.

James Oliver, David J Webb.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12433774      PMCID： PMC1124646          DOI： 10.1136/bmj.325.7373.1174/a

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  6 in total

1.  Sildenafil ameliorates effects of inhaled nitric oxide withdrawal.

Authors:  A M Atz; D L Wessel
Journal:  Anesthesiology       Date:  1999-07       Impact factor: 7.892

2.  Indian doctor in protest after using Viagra to save "blue babies".

Authors:  Sanjay Kumar
Journal:  BMJ       Date:  2002-07-27

Review 3.  Prescribing unlicensed drugs or using drugs for unlicensed indications.

Authors: 
Journal:  Drug Ther Bull       Date:  1992-12-07

4.  Sildenafil inhibits hypoxia-induced pulmonary hypertension.

Authors:  L Zhao; N A Mason; N W Morrell; B Kojonazarov; A Sadykov; A Maripov; M M Mirrakhimov; A Aldashev; M R Wilkins
Journal:  Circulation       Date:  2001-07-24       Impact factor: 29.690

5.  Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension.

Authors:  Lara S Shekerdemian; Hanne B Ravn; Daniel J Penny
Journal:  Am J Respir Crit Care Med       Date:  2002-04-15       Impact factor: 21.405

6.  Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide.

Authors:  Evangelos Michelakis; Wayne Tymchak; Dale Lien; Linda Webster; Kyoko Hashimoto; Stephen Archer
Journal:  Circulation       Date:  2002-05-21       Impact factor: 29.690
  6 in total
  3 in total

Review 1.  Sildenafil for pulmonary hypertension in neonates.

Authors:  Lauren E Kelly; Arne Ohlsson; Prakeshkumar S Shah
Journal:  Cochrane Database Syst Rev       Date:  2017-08-04

Review 2.  Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.

Authors:  Hossein A Ghofrani; Ian H Osterloh; Friedrich Grimminger
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

Review 3.  Modulating cGMP to treat lung diseases.

Authors:  Hossein-Ardeschir Ghofrani; Friedrich Grimminger
Journal:  Handb Exp Pharmacol       Date:  2009
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.